锦波生物（920982）12月9日大宗交易平台出现一笔成交，成交量2.50万股，成交金额750.00万元，大宗 交易成交价为300.00元，相对今日收盘价溢价28.58%。该笔交易的买方营业部为中信证券股份有限公司 大连高新园区证券营业部，卖方营业部为华泰证券股份有限公司南京长江路证券营业部。 进一步统计，近1个月内该股累计发生4笔大宗交易，合计成交金额为2124.00万元。 证券时报·数据宝统计显示，锦波生物今日收盘价为233.31元，上涨0.62%，日换手率为1.64%，成交额 为2.11亿元，近5日该股累计上涨4.42%。（数据宝） 12月9日锦波生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | | | | | | | | （%） | | | | 2.50 | 750.00 | 300.00 | 28.58 | 中信证券股份有限公司 大连高新园区证券营业 | 华泰证券股份有限公司 南京长江路证券营业部 | | | ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 每日经济新闻 （记者 曾健辉） 每经讯，2025年12月9日，北交所上市公司锦波生物（920982，收盘价：233.31元）发生一笔大宗交易，成交价300元/股，成交 数量2.5万股，成交金额750万元，溢价28.58%。买入营业部是中信证券股份有限公司大连高新园区证券营业部，卖出营业部是 华泰证券股份有限公司南京长江路证券营业部。 ...

Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

北交所策略专题报告 2025 年 12 月 07 日 北交所做市公司家数增长，做市商"择优而市"向核心指数汇集 ——北交所策略专题报告 北交所研究团队 诸海滨（分析师） zhuhaibin@kysec.cn 证书编号：S0790522080007 北交所做市公司数增至 143 家和北证 50 和北证专精特新指数重合度较高。 2025 年 10 月 24 日北交所、全国股转公司对证券公司 2025 Q1-3 的执业质量情况 进行了评价，合计有 21 家券商获得北交所做市得分。从有做市商的企业市值规 模和数量来看，整体队伍稳步"扩容"，截至 2025 年 12 月 5 日，北交所合计有 143 家企业有做市商，较 2024 全年增长 21.19%，北交所有做市商的企业总市值 达 4993.45 亿元。从收益率来看，有做市商的企业的涨幅以及成交更活跃，2025 年至今北交所有做市商的企业收益率达 48.51%，高于没有做市商企业的 39.11%，。从行业角度来看，做市公司中高端制造行业数量有 64 家，占比 44.76%。 从市值角度来看，20-50 亿市值企业占比最大，占比为 48.25%。从企业画像来看， 有做 ...

Core Viewpoint - The article emphasizes that despite the prevailing narrative of economic hardship, certain industries are thriving and generating significant profits, particularly in the context of Japan's "lost 30 years" and China's evolving consumer behavior [3][4]. Group 1: Economic Trends - The concept of a "low-desire society" does not equate to a lack of opportunities, as consumer demand is shifting towards different sectors [4]. - The article identifies eight key industries that are capitalizing on changing consumer preferences, highlighting the potential for growth in these areas [5]. Group 2: Key Industries - **Second-Hand Economy**: The second-hand luxury market in Japan, exemplified by "Daikokuya," has seen a surge in revenue, mirroring trends in China with platforms like "Hongbulin" and "Panghu" experiencing significant growth [6][7]. - **Pet Economy**: With a decline in birth rates, spending on pets has increased, with brands like "Inaba" in Japan and "Guobao" in China seeing strong stock performance [12][13][14]. - **Adult Care**: The adult diaper market in Japan has surpassed $10 billion, indicating a growing demand driven by an aging population [17][18]. - **Health Food and Beverages**: The rise in health consciousness has led to increased sales of sugar-free beverages and functional drinks, with brands like "Oriental Leaf" and "Dongpeng" gaining traction in China [21]. - **Beauty Economy**: The demand for beauty products remains strong, with high-priced collagen supplements and home beauty devices achieving significant sales [23][25]. - **Outdoor Recreation**: Companies in the outdoor equipment sector, such as "Snow Peak" in Japan, are thriving, reflecting a growing interest in outdoor activities [29][31]. - **Lazy Economy**: The trend towards convenience has boosted the frozen food market and smart home appliances, as consumers seek to save time [39][40]. - **Mental Well-being**: Products that provide emotional comfort, such as low-alcohol beverages and lifestyle brands, are gaining popularity, indicating a shift in consumer spending priorities [34][35]. Group 3: Investment Opportunities - The article suggests that the current economic climate presents unique opportunities for those willing to invest in counter-cyclical sectors, highlighting the importance of recognizing and acting on these trends [44].

Group 1 - The first batch of eight actively managed theme funds on the Beijing Stock Exchange (BSE) is set to enter its second open period, with an average cumulative return of nearly 100% over the past two years, outperforming major indices such as the ChiNext 50 and the BSE 50 by 50% [3][6][8] - As of December 5, 2025, the average cumulative return of these eight theme funds since inception is 62.31%, with some funds achieving returns exceeding 100%, the highest being 138% [3][6][7] - The total market value of publicly offered funds' heavy holdings in BSE stocks has shown a rising trend, surpassing 10 billion yuan in Q3 2025, indicating a more diversified investment approach [3][8] Group 2 - The BSE market has seen the issuance of 33 BSE 50 index funds, with a total scale of 13.3 billion yuan as of December 5, 2025, reflecting a steady growth in passive index fund offerings [10][11] - The overall price-to-earnings (PE) ratio of BSE A-shares remains at 44X, with daily trading volume averaging 13.9 billion yuan, indicating a stable market environment [20][23] - The BSE 50 index has reported a weekly increase of 1.49%, closing at 1,408.34 points, while the overall sentiment in the A-share market remains cautious amid upcoming significant meetings [17][25] Group 3 - The BSE has witnessed a total of 47 companies listed from January 1, 2024, to December 5, 2025, with one new company, Jingchuang Electric, listed in the week of December 1, 2025 [26][27] - The average issuance PE ratio for newly listed companies in 2024 is 13.79X, with an average first-day price fluctuation of 288% [12][13]

Group 1: Market Performance - As of December 5, 2025, the North Exchange A-share index consists of 286 stocks with an average market capitalization of 2.905 billion [18] - The North Exchange 50 index increased by 1.49% during the week of December 1 to December 5, closing at 1,408.34 points [18] - The average daily trading volume for the North Exchange A-shares reached 13.883 billion, a 4.24% increase from the previous week, with a daily turnover rate of 16.10% [18][19] Group 2: New Listings - Jingchuang Electric (stock code: 920035.BJ) was listed on December 2, 2025, focusing on the research, production, and sales of intelligent controllers for cold chain equipment, with 86.69% of its revenue coming from cold chain intelligent control products [2][27] - The company reported a gross margin of 45.55% for its core products, indicating strong profitability [2][27] Group 3: Investment Recommendations - The valuation gap between the North Exchange and the ChiNext is narrowing, suggesting increasing investment value, with PE ratios for North Exchange A-shares at 44.24 and ChiNext at 42.34 as of December 5, 2025 [28] - Short-term investment opportunities are recommended in sectors such as aerospace, humanoid robots, AI, and intelligent driving, while long-term focus should be on high-growth stocks with specialized attributes and strong earnings expectations [28]

Core Insights - The Chinese medical aesthetics industry has surpassed 300 billion yuan, with the light medical aesthetics market expected to grow at a compound annual growth rate (CAGR) of over 20% in the next five years, becoming the mainstream segment by 2024 [1] - Injection projects, as the core growth engine of light medical aesthetics, have seen their market size grow from 25.7 billion yuan in 2018 to 67 billion yuan in 2023, with a CAGR of 21.1%, projected to reach 147 billion yuan by 2027 [1] - The industry faces challenges such as rapid market changes driven by consumer preferences and increasing competition, necessitating innovation in material research to build competitive barriers [1] Market Dynamics - In 2024, the market share of injection materials is projected to be approximately 36% for hyaluronic acid, 29% for botulinum toxin, 19% for collagen, and 16% for regenerative materials [3] - The competition in the hyaluronic acid market has intensified, leading to revenue declines for major companies like Huaxi Biological and Aimeike, with revenue drops of 18.36% and 21.49% respectively in the first three quarters of 2025 [3][4] - In contrast, the recombinant collagen market is rapidly growing, with a projected CAGR of 44.93%, expected to reach 58.57 billion yuan by 2025 [3] Innovation and Product Development - Companies are accelerating new product launches to capture market opportunities, with Huaxi Biological introducing compliant products for facial skin improvement and other companies like Jinbo Biological launching innovative recombinant collagen products [5] - The emergence of new materials such as alginate and hydroxyapatite is set to enrich the market supply, with several products receiving regulatory approval in 2025 [6] Regulatory Environment - The industry is experiencing a shift towards compliance, with increased regulatory scrutiny leading to a "survival of the fittest" scenario, pushing medical aesthetic institutions to accelerate compliance transformations [2] - Despite the growth in compliant products, issues such as illegal operations and counterfeit products remain prevalent, posing risks to consumer safety [11][12] Pricing and Market Structure - The supply expansion has led to a restructuring of interests within the industry, with upstream manufacturers and downstream medical institutions engaged in pricing power struggles [8][9] - New platforms like Xinyang are disrupting traditional pricing models by significantly reducing costs through digitalization and centralized procurement, indicating a shift from a seller's market to a buyer's market [9][10] Future Trends - The industry is expected to evolve towards a more transparent and competitive landscape, with a focus on product and scenario-driven strategies, comprehensive treatment solutions, and enhanced consumer awareness [10] - The ongoing regulatory efforts and market dynamics suggest that the medical aesthetics industry is moving towards a more mature and compliant operational model, emphasizing innovation and safety [14]

Summary of 2025: "The End of the 14th Five-Year Plan" and Foundation Building - In 2025, the Beijing Stock Exchange (BSE) achieved multiple breakthroughs, with total market capitalization exceeding 820 billion yuan, number of accounts reaching 9.5 million, and average daily trading volume approaching 30 billion yuan, indicating a significant improvement in liquidity [4] - The market's "specialized, refined, distinctive, and innovative" characteristics became more pronounced, with national-level "little giants" accounting for 61%, fostering a group of high-growth, scarce enterprises in sectors such as new energy, robotics, and AI [4][10] - The quality of enterprises continued to improve, with the average net profit of newly listed companies increasing from 30 million yuan to 110 million yuan over three years [4] - As of the first three quarters of 2025, the median revenue and net profit of BSE companies were 293 million yuan and 22 million yuan, respectively, while the BSE 50 component stocks reached 508 million yuan and 46 million yuan, indicating stable business operations [4] Outlook for 2026: "The Beginning of the 15th Five-Year Plan" - The BSE will focus on "scarcity" and "new quality productivity" as dual main lines for deepening its layout, with policies expected to continue along the path of "Deep Reform 19 Articles" [4] - The average first-day increase of IPOs in the first 11 months of 2025 was 356%, with average subscription funds exceeding 640 billion yuan, suggesting a continuation of active performance in the new share market in 2026 [4] - The BSE will emphasize sectors such as technology manufacturing (AI supply chain, solid-state batteries, humanoid robots, intelligent driving), new materials (semiconductor materials, specialty fibers), and distinctive consumption (health, beauty, emotional consumption) [4] Market Characteristics and Investment Opportunities - The BSE has a unique market structure, with 65% of companies having a market capitalization of less than 2.5 billion yuan, while over 40% of BSE 50 companies exceed 5 billion yuan, indicating a small-cap characteristic [4][19] - The BSE's PE ratio reached 44 times as of November 21, 2025, with a valuation discount disappearing, and the PE ratio compared to the Sci-Tech Innovation Board has decreased to about 60%, highlighting investment value [4][29][34] - The BSE's industry distribution is more concentrated in mechanical equipment, power equipment, and basic chemicals compared to the ChiNext and Sci-Tech Innovation Board, aligning with its "specialized, refined, distinctive, and innovative" positioning [4][24][25] Performance and Growth Trends - The BSE's specialized and innovative component stocks showed the fastest revenue growth, with a year-on-year increase of 13% in the first three quarters of 2025 [35] - The median net profit of BSE 50 component stocks has surpassed that of the Sci-Tech Innovation Board and ChiNext, indicating a positive trend in profitability [40] - The overall profit growth rate of BSE companies is under pressure, but the specialized and innovative enterprises exhibit resilience, making them worthy of attention [40][41]

Core Insights - As of December 4, the total margin financing and securities lending balance on the Beijing Stock Exchange (BSE) was 7.516 billion yuan, a decrease of 9.0086 million yuan from the previous trading day, marking a continuous decline for three consecutive trading days [1] - The stocks with the highest margin financing balances included Jinbo Biological, Shuguang Digital Innovation, and Better Energy, with latest balances of 408 million yuan, 343 million yuan, and 313 million yuan respectively [1] - A total of 143 stocks on the BSE received net margin purchases on December 4, with 24 stocks having net purchases exceeding 1 million yuan, led by Chuangyuan Xinke with a net purchase of 7.9072 million yuan [1][2] Margin Financing Overview - The margin financing balance on December 4 was 7.515 billion yuan, down by 8.9486 million yuan from the previous day [1] - The securities lending balance was 634,100 yuan, a decrease of 60,000 yuan [1] - The average margin financing balance as a percentage of market capitalization for the top stocks was 1.40%, with leading stocks like Chenguang Cable, Audiwei, and Haidaer having ratios of 5.06%, 4.59%, and 4.10% respectively [1] Industry Performance - The industries with the highest concentration of stocks receiving net margin purchases over 1 million yuan were computer, electronics, and power equipment, with 4, 3, and 3 stocks respectively [2] - On December 4, stocks with net margin purchases over 1 million yuan had an average decline of 0.96%, with the top gainers being Sanxie Electric, Chuangyuan Xinke, and Fujida, which increased by 17.59%, 6.84%, and 1.82% respectively [2] - The average turnover rate for stocks with net margin purchases over 1 million yuan was 3.72%, with the highest turnover rates recorded for Sanxie Electric, Gais Food, and Chuangyuan Xinke at 39.13%, 14.54%, and 14.41% respectively [2] Notable Stocks - Stocks with the largest increases in margin financing on December 4 included Chuangyuan Xinke (increase of 7.9072 million yuan), Sanxie Electric (increase of 4.8019 million yuan), and Kaiter Co. (increase of 4.3903 million yuan) [2][3] - Other notable stocks with significant margin financing balances included Better Energy (31.332 billion yuan), Fujida (7.876 billion yuan), and Audiwei (14.560 billion yuan) [2][3]